A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Seasonal Influenza Vaccine in Adults

Inclusion Criteria

• Subjects who the investigator believes can and will comply with the requirements of the protocol
• A male or female 18 years of age or older, in stable health, as established by medical history and physical examination before entering into the study.
• Written informed consent obtained from the subject.
• Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line, or mobile, but NOT a pay phone or other multiple-user device.
• Female subjects of non-childbearing potential may be enrolled in the study.
• Female subjects of childbearing potential may be enrolled in the study, if the subject:
• - has practiced adequate contraception for 30 days prior to vaccination, and
• - has a negative pregnancy test on the day of vaccination, and
• - has agreed to continue adequate contraception during the entire treatment period and for 2 months after completion of the vaccination series.

Exclusion Criteria

• Use of an investigational / non-registered product other than the study vaccines within 30 days before study vaccination or planned use during study period.
• Planned administration or administration of a licensed vaccine within 30 days before study vaccination.
• Prior receipt of 2010/2011 influenza vaccine.
• Receipt of any investigational or approved influenza vaccine within six months of the first study visit.
• Any known or suspected allergy to any constituent of influenza vaccines ; a history of anaphylactic-type reaction to constituent of vaccine; or a history of severe adverse reaction to a previous influenza vaccine.
• History of any reaction or hypersensitivity likely to be exacerbated by any component of the vaccines.
• History of Guillain-Barre syndrome within 6 weeks of receipt of prior inactivated influenza virus vaccine.
• Presence or evidence of substance abuse or of neurological or psychiatric diagnoses which, even if clinically stable, are deemed by the investigator to render the potential subject unable / unlikely to provide accurate safety reports.
• Acute, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, based on history and physical examination.
• Presence of significant uncontrolled chronic medical or neuropsychiatric illness, based on history and physical examination
• Any confirmed or suspected immunosuppressive or immunodeficient condition, based on medical history and physical examination.
• Any significant disorder of coagulation or treatment with Coumadin derivatives or heparin
• Chronic administration of immunosuppressants or other immune-modifying drugs within 3 months prior to the first vaccine/product dose.
• Administration of immunoglobulins and/or any blood products within the 3 months preceding the first dose of study vaccine or planned administration during the study period.
• Pregnant or lactating female.
• Fever at the time of enrolment.
• Acute disease at the time of enrolment
• Any other condition which, in the opinion of the Investigator, prevents the subject from participating in the study.